Psychedelic Research
Sunstone powers trials to address complex mental health challenges and disorders while training therapists and optimizing the healing potential for patients.
Trials & Research
Trial administration and execution.
Establishing partnerships with academic institutions and pharmaceutical companies expands our wealth of knowledge. Sunstone utilizes the data we collect to inform the continual development and refinement of our guidelines and best practices so we can continue to operate trials safely and effectively.
Therapist Training
Prepare therapists via experiential simulations. Designed by experts with deep experience in psychedelic medicine, our unique training program in psychedelic-assisted therapy delivers core knowledge, hands-on experience, and in-depth evaluation.
Patient Experience
Sunstone is dedicated to developing and refining the optimal patient experience. Our ongoing commitment to conducting rigorous trials and extensive research will lead the way in establishing and advancing standards of patient care in psychedelic-assisted therapy.
Explore Patient Care
“I am very grateful for the exceptional care I received at Sunstone Therapies. The team’s profound experience and genuine compassion created an environment where I felt fully supported and secure at every stage of the process.”
Study Participant
Sunstone Published Research
Explore our growing list of published research featured in medical journals and publications.
-
Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
Read More: Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
-
Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
Read More: Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
-
Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
Read More: Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
-
Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” J Palliat Med, Aug. 2023.
Read More: Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” J Palliat Med, Aug. 2023.
-
Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
Read More: Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
-
Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?
Read More: Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?
-
The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder
Read More: The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder